相关实验视频

Updated: May 24, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

细胞癌治疗的最新进展

Yu-Wei Chen¹, Justine Panian², Brent Rose³

¹Division of Hematology Oncology, Department of Medicine, University of California San Diego School of Medicine, San Diego, CA.

JCO oncology practice

|March 6, 2025

概括

新型疗法,包括免疫检查点抑制剂 (ICI) 和贝尔祖提凡,已显著改善了晚期细胞癌 (RCC) 的治疗结果. 目前的证据不鼓励ICI重新挑战,强调战略测序以获得更好的整体生存率.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
药理学药理学是指药理学的学科.

背景情况:

细胞癌 (RCC) 管理已经发展到新的治疗方法.
免疫检查点抑制剂 (ICI) 已经改变了高级和转移性RCC护理.
基于ICI的组合提供了更好的生存结果.

研究的目的:

审查目前关于基于免疫的组合和RCC的新药的证据.
为RCC.提供对治疗顺序策略的见解.
评估新治疗剂在RCC管理中的有效性.

主要方法:

对临床试验数据和关于RCC治疗的出版文献的审查.
对基于ICI的组合和新药的生存结果的分析.
评估治疗顺序和重新挑战策略的评估.

主要成果:

基于ICI的组合 (nivolumab/ipilimumab,pembrolizumab/axitinib,nivolumab/cabozantinib,pembrolizumab/lenvatinib) 改善了第一线高级RCC的整体存活率 (OS).
辅助 pembrolizumab 是唯一的辅助疗法延长OS在切除高风险的RCC.
贝尔祖蒂芬为ICI和VEGF TKI后的发展提供了一个新的选择;一般来说,不鼓励重新挑战ICI.

结论:

基于免疫的组合和像贝尔祖提凡这样的新药代表了RCC治疗的重大进步.
治疗的战略顺序对于优化患者的治疗结果至关重要.
对最佳治疗途径和组合疗法的进一步研究是有必要的.

更多相关视频

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...